You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
|
|---|---|
| Published in |
Journal of Clinical Oncology, October 2013
|
| DOI | 10.1200/jco.2012.47.4189 |
| Pubmed ID | |
| Authors |
David R. Spigel, Thomas J. Ervin, Rodryg A. Ramlau, Davey B. Daniel, Jerome H. Goldschmidt, George R. Blumenschein, Maciej J. Krzakowski, Gilles Robinet, Benoit Godbert, Fabrice Barlesi, Ramaswamy Govindan, Taral Patel, Sergey V. Orlov, Michael S. Wertheim, Wei Yu, Jiping Zha, Robert L. Yauch, Premal H. Patel, See-Chun Phan, Amy C. Peterson |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 17% |
| Ireland | 1 | 17% |
| United States | 1 | 17% |
| Unknown | 3 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Practitioners (doctors, other healthcare professionals) | 2 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 226 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 1% |
| France | 2 | <1% |
| Ecuador | 2 | <1% |
| United Kingdom | 1 | <1% |
| Switzerland | 1 | <1% |
| Denmark | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 215 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 58 | 26% |
| Student > Ph. D. Student | 29 | 13% |
| Other | 28 | 12% |
| Student > Bachelor | 21 | 9% |
| Student > Master | 19 | 8% |
| Other | 39 | 17% |
| Unknown | 32 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 89 | 39% |
| Biochemistry, Genetics and Molecular Biology | 32 | 14% |
| Agricultural and Biological Sciences | 31 | 14% |
| Nursing and Health Professions | 5 | 2% |
| Chemistry | 5 | 2% |
| Other | 23 | 10% |
| Unknown | 41 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2024.
All research outputs
#1,937,157
of 25,374,647 outputs
Outputs from Journal of Clinical Oncology
#4,649
of 22,046 outputs
Outputs of similar age
#17,543
of 222,253 outputs
Outputs of similar age from Journal of Clinical Oncology
#58
of 244 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,046 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 222,253 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 244 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.